# Ionis Pharmaceuticals

the antisense pioneer; the FDA has accepted for Priority Review the New Drug Application for zilganersen in Alexander disease, and Ionis has licensed zilganersen to Recordati for all countries outside the US, extending its Spinraza (nusinersen, SMA) heritage.

Source: https://en.bioecon.ru/companies/ionis/
Updated: 2026-07-11

- Country: United States
- Ticker: IONS

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Capacity | new Oceanside facility more than double the size of existing Carlsbad facility | https://ir.ionis.com/news-releases/news-release-details/ionis-announces-plan-new-manufacturing-facility-oceanside-calif |
| Certification | LEED Silver certification for main Carlsbad headquarters; new research facility designed for LEED Gold certification | https://ionis.com/sites/default/files/2024-08/Ionis-2023-Corporate-Responsibility-Report.pdf |
| Regulatory approval | Zilganersen granted FDA Breakthrough Therapy, Orphan Drug, Rare Pediatric Disease, and Fast Track designations; NDA accepted for Priority Review with PDUFA date September 22, 2026 | https://ir.ionis.com/news-releases/news-release-details/ionis-announces-zilganersen-new-drug-application-alexander, https://ir.ionis.com/news-releases/news-release-details/zilganersen-granted-us-fda-fast-track-designation-people-living, https://www.neurologylive.com/view/fda-accepts-zilganersen-new-drug-application-priority-review-alexander-disease |
| Production site | Carlsbad, California (existing development chemistry and manufacturing facility); Oceanside, California (new manufacturing facility) | https://ionis.com/about-us/corporate-responsibility/2025-Corporate-Responsiblity-Report.pdf, https://ir.ionis.com/news-releases/news-release-details/ionis-announces-plan-new-manufacturing-facility-oceanside-calif |
| Headcount | Approximately 1,138 to 1,500 employees [medium confidence] | https://ionis.com/media-center/corporate-factsheet.pdf |
| Revenue | $944 million for full year 2025; $267.9 million for first quarter 2026 | https://ir.ionis.com/node/34176/pdf, https://www.sec.gov/Archives/edgar/data/874015/000087401526000251/form10q.htm |

Independent sources: neurologylive.com, sec.gov

## Technologies

- [Nucleic acid therapeutics (oligonucleotides)](https://en.bioecon.ru/technology/nucleic-acid-therapeutics/)